New mRNA tech takes aim at shingles in early human trial
NCT ID NCT07285265
Summary
This is an early-stage study testing a new type of shingles vaccine that uses mRNA technology. It aims to see if the vaccine is safe and triggers a good immune response in 180 healthy adults aged 40 and older. Participants will receive two shots about two months apart, and researchers will closely monitor for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VARICELLA-ZOSTER VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rongshui Miao Autonomous County Center for Disease Control and Prevention
Liuchow, Rongshui, China
Conditions
Explore the condition pages connected to this study.